ReviewClinical microbiology reviews2014
Escherichia coli ST131, an intriguing clonal group.
Review in Clinical microbiology reviews, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 489 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Epidemiology of ST131 in Besançon University Hospital
A Pilot Study of Fecal Microbiota Transplant (FMT) and Its Effects in Patients With Crohn's Disease With Moderate-to-High Risk of Colonization of Adherent-Invasive E. Coli (AIEC)
Who cites it
489 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Iran's Escherichia coli AMR Landscape (2010-2025): A One Health Systematic Review and Meta-Analysis.MicrobiologyOpen · 2026Pooled it
- Tracking of multidrug-resistant pathogen clones in Ghana: a systematic review and meta-analysis.BMC medical genomics · 2025Pooled it
- Efficacy andAntimicrobial agents and chemotherapy · 2025Trial
- Genomic profile of extraintestinal pathogenicVirulence · 2026Article
- Diverse Genetic Lineages Spreading Across Healthcare and Community Boundaries Underlie Extended-Spectrum Cephalosporin-Resistant Enterobacterales Colonization Burden in Botswana.The Journal of infectious diseases · 2026Article
- Comparative Genomic Analysis of Multidrug-Resistant Escherichia coli Across Poultry-Human-Environmental Interfaces.MicrobiologyOpen · 2026Article
- Whole-Genome Sequencing ofMicroorganisms · 2026Article
- Development and clinical validation of a CRISPR/Cas9-engineered reporter phage cocktail for rapid detection ofMicrobiology spectrum · 2026Article
- metaWEPP: leveraging biobank-scale intra-species phylogenies for near-haplotype resolution in metagenomic analysis.NAR genomics and bioinformatics · 2026Article
- Characterisation of Haemolytic Uropathogenic Escherichia coli Isolated From Dogs and Cats.Veterinary medicine and science · 2026Article
- Mapping the evolutionary path towards multi-drug resistance in the pandemicMicrobial genomics · 2026Article
- Microbiome features associated with persistent intestinal carriages of Escherichia coli ST131 in a Southeast Asian cohort study.Nature communications · 2026Article
- Genomic Insights and Antimicrobial Resistance Profiling of DiarrheagenicMicroorganisms · 2026Article
- Machine learning-based prediction of E. coli infection in hospitalized patients using a no-code analytical framework.Scientific reports · 2026Article
- Enrichment of the high-risk ST131 clone among ciprofloxacin-resistant Escherichia coli in a single-center cohort from Turkey: a molecular surveillance study.BMC infectious diseases · 2026Article
- Loss of O-antigen due toScience advances · 2026Article
- Influence of housing system on antimicrobial resistance and population structure of extended-spectrum beta-lactamase-producing Escherichia coli in South Korean layer farms.Poultry science · 2026Article
- Fosfomycin Resistance in Escherichia coli: Mechanisms, Trends, and Clinical Challenges.Cureus · 2026Review
- Antimicrobial Susceptibility Profiles of Extended-Spectrum β-Lactamase-Producing Escherichia coli Isolated From Intensively Reared and Free-Range Chickens in Selected Districts of Zambia.Veterinary medicine and science · 2026Article
- Article
429 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2008, a previously unknown Escherichia coli clonal group, sequence type 131 (ST131), was identified on three continents. Today, ST131 is the predominant E. coli lineage among extraintestinal pathogenic E. coli (ExPEC) isolates worldwide. Retrospective studies have suggested that it may originally have risen to prominence as early as 2003. Unlike other classical group B2 ExPEC isolates, ST131 isolates are commonly reported to produce extended-spectrum β-lactamases, such as CTX-M-15, and almost all are resistant to fluoroquinolones. Moreover, ST131 E. coli isolates are considered to be truly pathogenic, due to the spectrum of infections they cause in both community and hospital settings and the large number of virulence-associated genes they contain. ST131 isolates therefore seem to contradict the widely held view that high levels of antimicrobial resistance are necessarily associated with a fitness cost leading to a decrease in pathogenesis. Six years after the first description of E. coli ST131, this review outlines the principal traits of ST131 clonal group isolates, based on the growing body of published data, and highlights what is currently known and what we need to find out to provide public health authorities with better information to help combat ST131.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.